Illumina, Inc. vs Uranium Energy Corp — how do they compare? Illumina, Inc. trades at $278.17 (market cap $39.95B), while Uranium Energy Corp trades at $9.19 (market cap $4.53B). The key difference: Illumina, Inc. is far larger — about 8.8× Uranium Energy Corp's market cap, and Illumina, Inc. is trading nearer its 52-week high, Uranium Energy Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Uranium Energy Corp for 37 Days on average.
| ILMN | UEC | |
|---|---|---|
Market Cap | $39.95B | $4.53B |
Volume | 3,169,503 | 10,888,578 |
Sector | Health | Energy |
52-Week High | $293.69 | $20.14 |
52-Week Low | $91.00 | $9.04 |
Typical Hold Time | 83 Days | 37 Days |
Enterprise Value | $41.31B | $4.03B |
Signals from Pluang's Aura AI — not financial advice
ILMN trades at $264.40, down 1.25% on the day, but remains near its recent 52-week high of $278.99 (Defense World, 2026-10-01). The stock has surged 94.9% year-to-date (Zacks Investment Research, 2026-09-24), supported by strong earnings beats in recent quarters and a bullish technical trend. Fundamentals show a significant turnaround, with 2025 net income reaching $850 million after prior losses, though valuation ratios like a P/E of 49.36 are elevated. The pending inclusion in the S&P 500 (PRNewsWire, 2026-09-04) adds a positive catalyst.
The outlook is positive, driven by sequencing growth, AI integration in genomics, and improved profitability. However, risks include high valuation sensitivity, cost volatility, and competitive pressures in the life sciences sector. Analyst consensus is bullish with a 54% buy rating, but the average price target of $241 suggests limited near-term upside from current levels.
Uranium Energy (UEC) trades at $9.19, down 2.96% in the last session. The stock shows bearish technical signals with negative earnings momentum, posting losses in recent quarters despite revenue growth. The company is expanding its US uranium mining operations with two active mines, benefiting from increased government demand for domestic nuclear fuel. Analyst sentiment remains overwhelmingly positive with 87.5% buy ratings and a $16.06 consensus price target, though fundamental metrics show significant losses with a -368.62% net income margin.
UEC presents a high-risk, high-reward opportunity with strong Wall Street support but concerning financials. The bullish case hinges on nuclear energy expansion and domestic uranium demand growth, while risks include sustained operational losses, unproven production sustainability, and heavy reliance on financing activities. Current valuation appears stretched given negative profitability metrics.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →